The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS). VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions, filling an unmet […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!